Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors

2012314 citationsJournal Articlebronze Open Access

Authors

Ian E. Krop · Moffitt Cancer Center

Tim Demuth · Princess Margaret Cancer Centre

Tina Guthrie · Moffitt Cancer Center

Patrick Y. Wen · University of California, San Diego

Warren Mason · Wayne State University

Prakash Chinnaiyan · University of California, San Diego

Nicholas Butowski

Abstract

MK-0752 toxicity was schedule dependent. Weekly dosing was generally well tolerated and resulted in strong modulation of a Notch gene signature. Clinical benefit was observed, and rational combination trials are currently ongoing to maximize clinical benefit with this novel agent.

Topics & Keywords

Cancer Cells and Metastasis Developmental Biology and Gene Regulation Hedgehog Signaling Pathway Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 30, Issue 19, pp. 2307-2313

DOI: 10.1200/jco.2011.39.1540

Field-Weighted Citation Impact: 16.05